• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Amneal Pharmaceuticals Inc. (Amendment)

    12/12/23 6:04:36 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRX alert in real time by email
    SC 13G/A 1 tm2332489d1_sc13ga.htm SC 13G/A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 3)*

     

    Amneal Pharmaceuticals, Inc.
    (Name of Issuer)
     
    Class A Common Stock, par value US$0.01 per share
    (Title of Class of Securities)
     
    03168L105
    (CUSIP Number)
     
    November 7, 2023
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)

     

      x Rule 13d-1(c)

     

      ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    SCHEDULE 13G

     

    CUSIP No.      03168L105  

     

    1 Names of Reporting Persons
    Ambient Impact (HK) Limited
    2 Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  x
    (b)  ¨
    3 SEC Use Only
     
    4 Citizenship or Place of Organization
    Hong Kong

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:

     

    5 Sole Voting Power
    0
    6 Shared Voting Power
    16,438,356 (1)
    7 Sole Dispositive Power
    0
    8 Shared Dispositive Power
    16,438,356 (1)

    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    16,438,356 (1)
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    ¨
    11 Percent of Class Represented by Amount in Row (9)
    5.4% (2)
    12 Type of Reporting Person (See Instructions)
    CO

     

    (1)Number of shares is number of Class A Common Stock, par value US$0.01 per share ("Class A Common Stock") of Amneal Pharmaceuticals, Inc. (the “Issuer”).

     

    (2)This percentage is calculated based on 306,544,199 shares of Class A Common Stock outstanding, as described in the Agreement and Plan of Merger filed as Exhibit 2.1 to the Issuer’s Form 8-K, filed on November 8, 2023.

     

    Page 2 of 7 

     

     

    SCHEDULE 13G

     

    CUSIP No.      03168L105  

     

    1 Names of Reporting Persons
    Fosun International Limited
    2 Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  x
    (b)  ¨
    3 SEC Use Only
     
    4 Citizenship or Place of Organization
    Hong Kong

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:

     

    5 Sole Voting Power
    0
    6 Shared Voting Power
    18,407,656 (1)
    7 Sole Dispositive Power
    0
    8 Shared Dispositive Power
    18,407,656 (1)

    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    18,407,656 (1)
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    ¨
    11 Percent of Class Represented by Amount in Row (9)
    6.0% (2)
    12 Type of Reporting Person (See Instructions)
    CO

     

    (1)Number of shares is number of Class A Common Stock of the Issuer. Fosun International Limited beneficially owns 18,407,656 shares of Class A Common Stock of the Issuer, consisting of (i) 16,438,356 shares of Class A Common Stock held directly by Ambient Impact (HK) Limited, a wholly-owned subsidiary of Fosun International Limited; (ii) 1,642,300 shares of Class A Common Stock held directly by Fosun Atlas Capital SICAV RAIF S.C.S., a fund managed by a wholly-owned subsidiary of Fosun International Limited; and (iii) 327,000 shares of Class A Common Stock held directly by Peak Reinsurance Company Limited, a majority-owned subsidiary of Fosun International Limited.

     

    (2)This percentage is calculated based on 306,544,199 shares of Class A Common Stock outstanding, as described in the Agreement and Plan of Merger filed as Exhibit 2.1 to the Issuer’s Form 8-K, filed on November 8, 2023.

     

    Page 3 of 7 

     

     

    Item 1.  

     

    (a)Name of Issuer:

     

    Amneal Pharmaceuticals, Inc. 

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    400 Crossing Boulevard

    Bridgewater, NJ 08807

     

    Item 2.  

     

    (a)Name of Person Filing:

     

    This Schedule 13G is filed by Ambient Impact (HK) Limited (“Ambient Impact”), a company organized under the laws of the Hong Kong Special Administrative Region of China (“Hong Kong”), and Fosun International Limited (“Fosun International”, together with Ambient Impact, the “Reporting Persons”), a company organized under the laws of Hong Kong.

     

    Ambient Impact is an indirectly wholly-owned subsidiary of Fosun International.

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office for Ambient Impact is 5/F, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong. The address of the principal business office for Fosun International is Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong.

     

    (c)Citizenship:

     

    See Item 2(a)

     

    (d)Title of Class of Securities:

     

    Class A Common Stock of the Issuer

     

    (e)CUSIP No.:

     

    03168L105

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
         
    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Page 4 of 7 

     

     

    Item 4.Ownership.

     

      (a) See Item 9 of the cover pages to this Schedule 13G for the aggregate number of Class A Common Stock that are beneficially owned by each Reporting Person as of December 12, 2023.

     

      (b) See Item 11 of the cover pages to this Schedule 13G for the percentage of Class A Common Stock that are beneficially owned by each Reporting Person as of December 12, 2023.

     

      (c) See Items 5 through 8 of the cover pages to this Schedule 13G for the number of Class A Common Stock that are beneficially owned by each Reporting Person as of December 12, 2023 as to which there is sole or shared power to vote or direct the vote, and sole or shared power to dispose or direct the disposition.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    See Item 2.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

      

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Page 5 of 7 

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: December 12, 2023

     

    AMBIENT IMPACT (HK) LIMITED  
         
    By: /s/ Ma King Yin  
      Ma King Yin  
      Director  
         
    FOSUN INTERNATIONAL LIMITED  
         
    By: /s/ SZE Mei Ming  
      SZE Mei Ming  
      Company Secretary  

     

    Page 6 of 7 

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
         
    99.1   Joint Filing Agreement dated September 28, 2018 by and between Ambient Impact (HK) Limited and Fosun International Limited (incorporated by reference to Exhibit 99.1 to that certain Schedule 13G filed on September 28, 2018 by the Reporting Persons with the Securities and Exchange Commission).

     

    Page 7 of 7 

     

     

    Get the next $AMRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMRX

    DatePrice TargetRatingAnalyst
    6/6/2025$12.00Buy
    Goldman
    2/24/2025$9.00 → $12.00Neutral → Overweight
    Analyst
    9/6/2024$9.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $AMRX
    SEC Filings

    See more
    • Amneal Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

      5/8/25 4:21:09 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Amneal Pharmaceuticals Inc.

      10-Q - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

      5/7/25 4:39:31 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

      5/2/25 6:18:24 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Amneal Pharmaceuticals with a new price target

      Goldman initiated coverage of Amneal Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      6/6/25 8:33:10 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Pharmaceuticals upgraded by Analyst with a new price target

      Analyst upgraded Amneal Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously

      2/24/25 7:02:03 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Pharmaceuticals upgraded by JP Morgan with a new price target

      JP Morgan upgraded Amneal Pharmaceuticals from Underweight to Neutral and set a new price target of $9.00

      9/6/24 7:29:08 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patel Gautam sold $761,146 worth of shares (94,906 units at $8.02), decreasing direct ownership by 6% to 1,609,144 units (SEC Form 4)

      4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

      6/18/25 4:11:43 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Patel Gautam sold $452,537 worth of shares (56,426 units at $8.02), decreasing direct ownership by 3% to 1,704,050 units (SEC Form 4)

      4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

      6/12/25 4:19:17 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive Vice President Shah Nikita sold $372,481 worth of shares (49,140 units at $7.58), decreasing direct ownership by 11% to 388,929 units (SEC Form 4)

      4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

      5/19/25 4:16:23 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

      Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte®. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third quarter of 2025. Prednisolone acetate ophthalmic suspension, USP 1% is a sterile, topical anti-inflammatory agent for ophthalmic use and is indicated for treating steroid-respo

      6/12/25 8:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal to Participate at Upcoming Investor Conferences in June

      BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5, 2025, with company presentation at 9:20 AM ET, and Goldman Sachs Global Healthcare Conference on June 10, 2025, with fireside chat at 10:40 AM ET. Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Executive Vice President and Chief Financial Officer, will participate in both conferences. A live webcast will be accessible at https://investors.amneal.com with replays available following both events. About AmnealAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX), headquartered

      5/29/25 4:05:00 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

      Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya® (dihydroergotamine mesylate) injection, the first and only dihydroergotamine (DHE) autoinjector for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.1,2 Brekiya autoinjector provides patie

      5/15/25 8:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Amneal Pharmaceuticals Inc.

      SC 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

      11/14/24 4:11:34 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Amneal Pharmaceuticals Inc.

      SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

      10/31/24 6:51:29 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Amneal Pharmaceuticals Inc. (Amendment)

      SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

      5/13/24 4:15:28 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRX
    Financials

    Live finance-specific insights

    See more
    • Amneal Reports First Quarter 2025 Financial Results

      ‒ Q1 2025 Net Revenue of $695 million; GAAP Net Income of $12 million; Diluted Income per Share of $0.04 ‒ ‒ Adjusted EBITDA of $170 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Affirming 2025 Full Year Guidance ‒ Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced its results for the first quarter ended March 31, 2025. "Amneal delivered another strong quarter to start 2025, with broad-based growth across all three segments driven by our team's outstanding execution. We are very pleased with the commercial uptake of CREXONT® for Parkinson's Disease and the momentum of our recently launched injectable products, which are delivering tremendous value to pat

      5/2/25 6:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal to Report First Quarter 2025 Results on May 2, 2025

      Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced that the Company will release its first quarter 2025 financial results on Friday, May 2, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this here. The access code for the call

      4/8/25 4:05:00 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

      ‒ Full Year 2024 Performance Met or Exceeded All Financial Guidance Metrics – ‒ Q4 2024 Net Revenue of $731 million; GAAP Net Loss of $31 million; Diluted Loss per Share of $0.10 ‒ ‒ Q4 2024 Adjusted Net Income(1) of $40 million, Adjusted EBITDA(1) of $155 million; Adjusted Diluted EPS(1) of $0.12 ‒ ‒ Full Year 2024 Net Revenue of $2.79 billion; GAAP Net Loss of $117 million; Diluted Loss per Share of $0.38 ‒ ‒ Full Year 2024 Adjusted Net Income(1) of $187 million; Adjusted EBITDA(1) of $627 million; Adjusted Diluted EPS(1) of $0.58 ‒ ‒ Provides 2025 Financial Guidance of $3.0 to $3.1 billion in net revenue and $650 to $675 million in Adjusted EBITDA(1)(2) – Amneal Pharmaceuticals,

      2/28/25 6:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month

      Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced donations totaling $1.5 million to multiple patient assistance foundations that support individuals living with Parkinson's disease in honor of Parkinson's Awareness Month. These contributions underscore Amneal's ongoing commitment to the Parkinson's community by supporting patient care, education, and advocacy—and helping patients and caregivers navigate the unique challenges of living with the disease. Parkinson's disease affects more than 10 million people around the world. The progressive nature of the disease, along with the cost of treatment, often places signif

      4/11/25 8:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal to Ring the Nasdaq Closing Bell on April 2, 2024

      - Celebrating Amneal's recent listing on the Nasdaq Stock Exchange Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global pharmaceutical company, today announced that Chirag and Chintu Patel, Co-founders and Co-Chief Executive Officers, will ring the Nasdaq closing bell on Tuesday, April 2, 2024. "As entrepreneurs who founded Amneal in 2002, we are pleased to join the esteemed roster of Nasdaq-listed companies. Today Amneal is a growing global pharmaceutical leader with a diverse portfolio of essential medicines that help make healthy possible. Our focus on patient access and affordability allows us to improve countless lives, and our commitment to innovation a

      3/28/24 4:05:00 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deb Autor, Former FDA Deputy Commissioner, Appointed CEO of Healthcare Innovation Catalysts

      Ms. Autor will further HIC's role as a sought-after advisor to global life sciences organizations Healthcare Innovation Catalysts, Inc. (HIC), a leading provider of regulatory affairs, clinical advisory, quality, compliance, federal partnership, and strategic advisory services to global life sciences organizations, announced today that Deborah M. Autor, former Deputy Commissioner of the U.S. Food and Drug Administration (FDA), has joined the firm as its first Chief Executive Officer. In this role, Ms. Autor will build on HIC's deep bench of cross-functional technical expertise, furthering the company's role as a sought-after advisor in both the private and public sectors. This press rele

      2/1/24 7:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care